Technetium tc-99m oxidronate kit - Generic Drug Details

« Back to Dashboard

What are the generic sources for technetium tc-99m oxidronate kit and what is the scope of patent protection?

Technetium tc-99m oxidronate kit is the generic ingredient in one branded drug marketed by Curium and is included in one NDA. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for technetium tc-99m oxidronate kit

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	7
DailyMed Link:	technetium tc-99m oxidronate kit at DailyMed

US Patents and Regulatory Information for technetium tc-99m oxidronate kit

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Curium	TECHNESCAN HDP	technetium tc-99m oxidronate kit	INJECTABLE;INJECTION	018321-001	Approved Prior to Jan 1, 1982		RX	Yes	Yes

Expired US Patents for technetium tc-99m oxidronate kit

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Curium	TECHNESCAN HDP	technetium tc-99m oxidronate kit	INJECTABLE;INJECTION	018321-001	Approved Prior to Jan 1, 1982	4,432,963
Curium	TECHNESCAN HDP	technetium tc-99m oxidronate kit	INJECTABLE;INJECTION	018321-001	Approved Prior to Jan 1, 1982	4,497,744

# Technetium Tc-99m Oxidronate Kit Market Dynamics, Patent Status, and Financial Trajectory

Last updated: September 9, 2026

Technetium Tc-99m oxidronate kit is a mature skeletal-imaging radiopharmaceutical used to prepare technetium Tc-99m oxidronate injection for bone scintigraphy. Its commercial outlook is stable to declining in developed markets because conventional bone scans face substitution from PET imaging, including sodium fluoride F-18 and disease-specific tracers. The product has limited patent value, no meaningful molecule-level exclusivity, and revenue exposure concentrated in hospital nuclear-medicine departments, radiopharmacies, and government-backed isotope supply chains.

Product-level revenue is not publicly disclosed by most manufacturers. Financial performance is therefore best assessed through procedure volumes, radiopharmaceutical distribution, isotope availability, reimbursement, and substitution risk rather than reported sales for the kit alone.

What is technetium Tc-99m oxidronate kit used for?

Technetium Tc-99m oxidronate kit is an in vitro preparation kit. The nonradioactive kit is reconstituted with sodium pertechnetate Tc-99m to produce an injectable radiopharmaceutical for skeletal imaging.

Attribute	Description
Active imaging agent	Technetium Tc-99m oxidronate
Chemical class	Technetium-labeled diphosphonate
Primary use	Whole-body and regional bone scintigraphy
Main indications	Detection of osteoblastic activity, skeletal metastases, fractures, infection, and selected bone disorders
Administration	Intravenous
Radioisotope half-life	Approximately 6 hours for Tc-99m
Commercial format	Multidose or unit-dose sterile kit, depending on supplier
Supply model	Kit plus Tc-99m generator or radiopharmacy supply
Prescription status	Prescription radiopharmaceutical
Principal substitutes	Tc-99m medronate, Tc-99m methylene diphosphonate, Tc-99m pyrophosphate, F-18 sodium fluoride PET

The kit does not contain radioactive technetium at the point of manufacture. This distinction affects inventory, transportation, reimbursement, and product economics. Radiopharmacies typically compound the final product close to the imaging site because Tc-99m decays rapidly.

What is the FDA regulatory status of technetium Tc-99m oxidronate?

The FDA has approved technetium Tc-99m oxidronate products for skeletal imaging. A historically important U.S. product is TechneScan HDP, associated with Mallinckrodt Nuclear Medicine LLC and FDA NDA 018292. FDA labeling describes the product as a kit for the preparation of technetium Tc-99m oxidronate injection. [1]

The regulatory profile is mature:

Regulatory factor	Market impact
Approved indication	Skeletal imaging
Regulatory pathway	Full NDA approval for the reference product and abbreviated or equivalent pathways for qualifying products
Clinical development burden	Low relative to novel radiopharmaceuticals
Post-approval burden	Sterility, radiochemical purity, stability, manufacturing controls, and isotope-handling compliance
Exclusivity	No meaningful current new-drug exclusivity expected for a product first approved decades ago
Clinical differentiation	Limited
Primary regulatory risk	Manufacturing interruptions, quality deviations, and isotope supply disruption

The product’s regulatory value lies in established manufacturing and distribution capability, not in proprietary clinical data. FDA radiopharmaceutical oversight also extends to compounding, labeling, radionuclide purity, sterility, and final product release.

What patents protect technetium Tc-99m oxidronate kit?

The core composition is unlikely to have active U.S. patent protection. Oxidronate and the use of Tc-99m-labeled diphosphonates for skeletal imaging are mature technologies. Any original composition, preparation, or use patents would generally have expired after the standard patent term.

Patent category	Current commercial significance
Oxidronate composition patents	No meaningful remaining exclusivity expected
Tc-99m labeling patents	Original claims are generally expired or commercially weak
Bone-imaging method patents	Most early claims are expired
Kit formulation patents	Potentially relevant only if tied to a specific modern formulation or manufacturing process
Manufacturing-process patents	May protect process know-how, but rarely create broad market exclusivity
Device or packaging patents	Could affect a particular presentation without blocking the active ingredient

The Orange Book should be reviewed by NDA and product listing for the latest patent and exclusivity record. For this mature product class, the principal competitive barriers are sterile manufacturing, validated radiochemical production, regulatory compliance, isotope access, and distribution speed rather than enforceable composition patents. [2]

What is the Orange Book status of technetium Tc-99m oxidronate?

Technetium Tc-99m oxidronate has the characteristics of an old, abbreviated-competition radiopharmaceutical rather than a recently launched protected medicine. No commercially important active ingredient patent or pediatric exclusivity position is generally associated with the product class.

Orange Book relevance is limited for three reasons:

1. The product has been marketed for decades.
2. The active ingredient is a well-established skeletal-imaging agent.
3. Generic or therapeutically equivalent competition depends more on manufacturing and local radiopharmacy capability than on Paragraph IV patent litigation.

A Paragraph IV filing against an old oxidronate kit would have limited strategic value unless the listed patent covered a specific commercial formulation or manufacturing process. No major public Paragraph IV campaign is associated with technetium Tc-99m oxidronate comparable to disputes involving high-revenue small-molecule medicines.

When does technetium Tc-99m oxidronate lose exclusivity?

The practical exclusivity period ended long ago. The product’s original regulatory and patent protection is not a current barrier to entry.

Exclusivity layer	Expected position
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not applicable to the broad skeletal-imaging indication
Pediatric exclusivity	No material current role
Original composition patents	Expired
Method-of-use patents	Predominantly expired
Formulation patents	No broad active barrier generally associated with the class
Data exclusivity	Expired for legacy products

The relevant commercial question is not when exclusivity ends, but whether a supplier can maintain reliable production and delivery. A theoretically open market can still have limited competition because radiopharmaceutical kits require specialized facilities, quality systems, validated cold-chain logistics, and access to Tc-99m.

How strong is the patent estate for technetium Tc-99m oxidronate?

The patent estate is weak from a blocking-rights perspective and moderate only as a source of manufacturing know-how.

Patent strength can be assessed across four dimensions:

Dimension	Assessment
Composition-of-matter protection	Very weak or expired
Clinical-use protection	Weak and largely expired
Formulation protection	Limited, unless a supplier owns a narrow process or presentation claim
Manufacturing know-how	More important than patents, particularly for sterile kit production and radiochemical purity

A supplier may still obtain commercial protection from trade secrets, supplier qualification, production scale, regulatory history, and customer relationships. Those advantages are difficult for patent databases to capture.

What formulations are protected by technetium Tc-99m oxidronate?

The commercial kit typically contains oxidronate and reducing-agent components, including stannous salts, in a sterile formulation designed to permit radiolabeling with sodium pertechnetate Tc-99m. Exact excipient amounts, vial configuration, storage conditions, and reconstitution instructions depend on the approved label.

Formulation differentiation is narrow. Potentially relevant technical areas include:

• Radiochemical purity after reconstitution
• Stability during the labeled-use window
• Resistance to oxidation
• Vial vacuum and reconstitution performance
• Multidose versus unit-dose presentation
• Compatibility with automated radiopharmacy systems
• Sterility assurance and particulate control
• Reduced preparation time or improved labeling yield

These factors may support supplier preference but do not necessarily create enforceable market exclusivity.

What is the market outlook for technetium Tc-99m oxidronate?

The market is mature, fragmented, and operationally constrained. Demand is linked to bone-scan procedure volume rather than prescription growth.

Demand drivers

Bone scintigraphy remains useful when physicians need a relatively inexpensive whole-body assessment of osteoblastic activity. Demand is supported by:

• Prostate and breast cancer staging
• Evaluation of suspected osseous metastases
• Fracture and stress-injury assessment
• Osteomyelitis and prosthesis evaluation
• Limited PET availability in some regions
• Lower acquisition cost than PET
• Broad availability of gamma cameras

Technetium Tc-99m remains the most widely used diagnostic radioisotope in nuclear medicine. Its supply is linked to molybdenum-99 production, reactor operations, generator manufacturing, and radiopharmacy distribution. [3]

Demand constraints

The main pressure is substitution by PET and hybrid imaging. F-18 sodium fluoride PET can provide higher-resolution skeletal imaging, while PSMA PET has displaced conventional bone scans in parts of prostate-cancer staging. FDG PET also captures many metastatic and inflammatory indications.

The resulting demand pattern is mixed:

Market	Expected trajectory
United States	Flat to declining procedure demand
Western Europe	Mature to declining
Japan and other developed Asian markets	Mature, with reimbursement and demographic support
Emerging markets	Potential unit growth from expanding nuclear-medicine capacity
High-end oncology centers	Faster substitution to PET
Resource-constrained hospitals	Continued reliance on Tc-99m bone scans

What is the financial trajectory of technetium Tc-99m oxidronate?

The financial trajectory is likely characterized by stable but low-growth revenue, periodic price pressure, and margin sensitivity to manufacturing utilization and isotope logistics.

No major manufacturer generally reports technetium Tc-99m oxidronate revenue as a separate public segment. Financial exposure is embedded in broader nuclear-medicine or radiopharmaceutical businesses. Revenue can be modeled as:

Bone-scan procedure volume × kit utilization × net price per dose

Profitability is affected by:

• Kit production scale
• Sterile manufacturing utilization
• Tc-99m availability
• Radiopharmacy labor
• Short dating and inventory waste
• Transportation distance
• Contract pricing with hospitals and distributors
• Reimbursement for bone scintigraphy
• PET substitution

The kit itself is not the entire cost of the procedure. Hospitals also incur charges for the isotope, radiopharmacy preparation, imaging time, technologist labor, interpretation, and facility overhead.

Financial scenario analysis

Scenario	Demand effect	Margin effect	Strategic implication
Base case	Gradual decline in conventional bone scans	Stable to pressured	Maintain supply reliability and low-cost production
Upside case	Growth in emerging markets or isotope shortages affecting alternatives	Moderate improvement	Expand distribution and radiopharmacy contracts
Downside case	Faster PSMA PET and F-18 sodium fluoride adoption	Volume and margin decline	Reallocate capital to PET and targeted radiopharmaceuticals
Supply-disruption case	Temporary Tc-99m or manufacturing shortage	Short-term price volatility	Inventory and generator access become decisive

Which companies compete with technetium Tc-99m oxidronate?

Competition exists at both the product and modality level.

Direct product competition

Direct competitors include manufacturers of Tc-99m diphosphonate kits, particularly products based on medronate or methylene diphosphonate. Products may be therapeutically similar but differ in approved labeling, supply reliability, reconstitution characteristics, and local procurement status.

Modality competition

The more important competitive set includes:

• F-18 sodium fluoride PET
• PSMA PET for prostate-cancer staging
• FDG PET/CT
• MRI for marrow and soft-tissue assessment
• CT for cortical bone and structural evaluation
• Whole-body MRI in selected oncology settings

Technetium Tc-99m oxidronate remains cost-competitive where PET capacity is constrained. Its relative position is weaker in centers with high PET penetration and access to disease-specific tracers.

What patent litigation and settlement agreements affect the product?

No major publicly prominent patent litigation or settlement framework is associated with technetium Tc-99m oxidronate comparable to litigation involving protected branded drugs. The absence of major litigation is consistent with an old active ingredient, expired core patents, and a market in which operational supply barriers matter more than patent enforcement.

Potential disputes would more likely involve:

• Manufacturing quality
• FDA warning letters or recalls
• Contract supply
• Distribution rights
• Trademark or product presentation
• Procurement arrangements
• Compounding and radiopharmacy compliance

Patent litigation risk is low. Regulatory and supply-chain risk is more relevant.

What generic entry risks exist for technetium Tc-99m oxidronate?

Generic entry risk is structurally high because the active ingredient is mature and patent protection is weak. Commercial entry risk is different: the market may be difficult to enter profitably.

A new supplier must establish:

1. FDA-compliant sterile manufacturing.
2. Validated radiolabeling performance.
3. Reliable access to packaging and raw materials.
4. Radiopharmacy and distributor relationships.
5. Short-lead-time delivery capability.
6. Product release and quality-control infrastructure.
7. A response plan for isotope shortages and manufacturing interruptions.

This limits the number of effective competitors despite low legal exclusivity.

How does technetium Tc-99m oxidronate compare with Tc-99m medronate?

Factor	Tc-99m oxidronate	Tc-99m medronate
Clinical role	Bone scintigraphy	Bone scintigraphy
Technology maturity	Old, established	Old, established
Patent position	Core protection expired	Core protection expired
Differentiation	Limited	Limited
Substitution risk	PET and MRI	PET and MRI
Supply economics	Highly dependent on Tc-99m logistics	Highly dependent on Tc-99m logistics
Commercial advantage	Local availability and price	Local availability and price
Strategic outlook	Mature, low growth	Mature, low growth

Neither product has a durable molecule-level competitive moat. In practice, hospitals select between them based on formulary status, supplier reliability, labeling, price, and availability.

Key Takeaways

• Technetium Tc-99m oxidronate kit is a mature bone-imaging radiopharmaceutical with limited patent value.
• Original composition, method-of-use, and exclusivity protections are expected to have expired.
• No major Paragraph IV campaign, patent settlement, or blocking patent estate is associated with the product class.
• Revenue is not generally disclosed separately by manufacturers.
• Commercial performance depends on bone-scan volume, Tc-99m availability, radiopharmacy logistics, reimbursement, and PET substitution.
• The strongest competitive barriers are sterile manufacturing, regulatory compliance, isotope access, and distribution.
• The U.S. and Western European markets are likely flat to declining, while emerging markets may provide limited unit growth.
• PSMA PET, F-18 sodium fluoride PET, FDG PET, MRI, and CT represent the main competitive threats.
• Generic entry is legally feasible but operationally demanding.
• Financial exposure is best viewed as a mature, low-growth radiopharmaceutical franchise rather than a protected specialty-drug asset.

FAQs

Is technetium Tc-99m oxidronate a generic drug?

It is a mature radiopharmaceutical kit with generic-like competitive characteristics. Commercial equivalence depends on FDA approval, radiochemical performance, sterile manufacturing, and supply reliability.

Does the oxidronate kit contain radioactive material?

The kit normally contains nonradioactive ingredients. Tc-99m is added during preparation, typically using sodium pertechnetate obtained from a generator or radiopharmacy.

Can PET completely replace technetium Tc-99m oxidronate?

No. PET substitution is strongest in oncology centers with access to F-18 sodium fluoride, PSMA PET, or FDG PET. Cost, availability, reimbursement, and clinical workflow continue to support bone scintigraphy in many settings.

Is technetium Tc-99m oxidronate an attractive licensing asset?

Its value is usually operational rather than patent-based. Licensing may make sense where a partner contributes sterile manufacturing capacity, isotope distribution, hospital contracts, or geographic access.

What is the biggest investment risk for the product?

The largest long-term risk is declining procedure volume from PET and other imaging modalities. The largest near-term risk is supply disruption involving Tc-99m, kit manufacturing, quality release, or radiopharmacy distribution.

References

1. U.S. Food and Drug Administration. (n.d.). TechneScan HDP: Prescribing information and NDA record 018292. Drugs@FDA.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.
3. International Atomic Energy Agency. (2023). Molybdenum-99 and technetium-99m production and supply. IAEA.
4. Society of Nuclear Medicine and Molecular Imaging. (n.d.). Procedure standard for bone scintigraphy. SNMMI.
5. U.S. Food and Drug Administration. (n.d.). Radiopharmaceuticals and radioactive drug research. FDA.